4.20
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$4.05
Offen:
$4.08
24-Stunden-Volumen:
3.25M
Relative Volume:
0.61
Marktkapitalisierung:
$340.65M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.561
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
+0.48%
1M Leistung:
-40.26%
6M Leistung:
-39.48%
1J Leistung:
-34.07%
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ALT
Altimmune Inc
|
4.20 | 339.03M | 409.00K | -101.35M | -71.49M | -1.64 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-10 | Fortgesetzt | Goldman | Sell |
2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
2025-01-08 | Eingeleitet | Stifel | Buy |
2024-11-12 | Eingeleitet | UBS | Buy |
2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
2024-01-24 | Eingeleitet | Goldman | Neutral |
2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
2022-12-01 | Eingeleitet | Goldman | Buy |
2021-12-29 | Fortgesetzt | Jefferies | Buy |
2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
2021-02-11 | Eingeleitet | Guggenheim | Buy |
2020-12-14 | Eingeleitet | Jefferies | Buy |
2020-11-12 | Bestätigt | B. Riley Securities | Buy |
2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
2019-07-19 | Eingeleitet | ROTH Capital | Buy |
2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Is Altimmune Inc. a good long term investmentPowerful growth strategies - Autocar Professional
What drives Altimmune Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
What analysts say about Altimmune Inc. stockPowerful growth strategies - Autocar Professional
Shareholders Alert: Investigation Into Altimmune, Inc. (ALT)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Why Altimmune Inc. stock attracts strong analyst attentionRisk Adjusted Stock Signals - Newser
Lost Money on Altimmune, Inc. (ALT)? Contact Levi & Korsinsky About Fraud Investigation - ACCESS Newswire
Altimmune Inc. Stock Analysis and ForecastFree High-Return Strategy Alerts - Autocar Professional
Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsALT - ACCESS Newswire
Investors in Altimmune, Inc. (ALT) Warned of Potential Securities FraudContact Levi & Korsinsky Today - Newsfile
(ALT) Technical Pivots with Risk Controls - news.stocktradersdaily.com
ALT ALERT: Ongoing Investigation Into Altimmune, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Securities Litigation as a Strategic Tool: Lessons from Altimmune's Legal Challenges and the Role of the Schall Law Firm - AInvest
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Did Altimmune, Inc. (ALT) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Lost Investment in Altimmune, Inc. (ALT)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - WV News
What makes Altimmune Inc. stock price move sharplyFree Smart Money Stock Analysis - Newser
How Altimmune Inc. stock performs during market volatilityTrending Stock Alert - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - GlobeNewswire Inc.
OneDigital Investment Advisors LLC Sells 2,887 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Concurrent Investment Advisors LLC Purchases New Holdings in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune (NASDAQ:ALT) Upgraded to “Strong Sell” at The Goldman Sachs Group - Defense World
Altimmune (NASDAQ:ALT) Upgraded at The Goldman Sachs Group - Defense World
Pomerantz LLP investigates securities fraud claims in Altimmune's IMPACT Phase 2b trial. - AInvest
Altimmune (NASDAQ:ALT) Rating Increased to Strong Sell at The Goldman Sachs Group - Defense World
The Goldman Sachs Group Upgrades Altimmune (NASDAQ:ALT) to Strong Sell - Defense World
Altimmune (NASDAQ:ALT) Stock Rating Upgraded by The Goldman Sachs Group - Defense World
JMP Securities Lowers Altimmune (NASDAQ:ALT) Price Target to $15.00 - Defense World
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment - TipRanks
Altimmune falls after Goldman resumes coverage with "sell", citing competition - TradingView
Citizens JMP lowers Altimmune stock price target to $15 on fibrosis miss - Investing.com Nigeria
Goldman Sachs downgrades Altimmune stock to Sell on pemvidutide concerns - Investing.com Canada
Altimmune Plunges 14.56% on Goldman Sachs Downgrade - AInvest
Altimmune resumed with a Sell at Goldman Sachs - TipRanks
Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development - TipRanks
Altimmune enrolls first patient in ALD treatment trial By Investing.com - Investing.com South Africa
ATTENTION Altimmune, Inc. (ALT) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
How To Trade (ALT) - news.stocktradersdaily.com
Levi & Korsinsky Launches Fraud Investigation on Behalf of Altimmune, Inc. (ALT) Shareholders - ACCESS Newswire
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):